Last Updated : May 17, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name Sort ascending | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Imfinzi | durvalumab | Biliary tract cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Dupixent | dupilumab | atopic dermatitis | Do not reimburse | Complete | ||
| Dupixent | dupilumab | Asthma | Reimburse with clinical criteria and/or conditions | Complete | ||
| Dupixent | dupilumab | atopic dermatitis | Reimburse with clinical criteria and/or conditions | Complete | ||
| Dupixent | dupilumab | Asthma | Reimburse with clinical criteria and/or conditions | Complete | ||
| Dupixent | dupilumab | Atopic dermatitis, pediatrics | Reimburse with clinical criteria and/or conditions | Complete | ||
| Dupixent | dupilumab | atopic dermatitis | Reimburse with clinical criteria and/or conditions | Complete | ||
| Cymbalta | Duloxetine hydrochloride | Pain, Neuropathic, Diabetic | List with clinical criteria and/or conditions | Complete | ||
| Cymbalta | Duloxetine hydrochloride | Depressive, Major Disorder (MDD) | Do not list | Complete | ||
| Trulicity | dulaglutide | Diabetes mellitus, Type 2 | Reimburse with clinical criteria and/or conditions | Complete |
Last Updated : May 17, 2024